hero section gradient
15 handpicked stocks

Japan's Tariff-Driven Supply Chain Shift

As US tariffs threaten Japanese exports, manufacturers are looking to relocate production to tariff-friendly countries like Mexico and Canada. This carefully selected group of stocks represents companies positioned to benefit from this major supply chain realignment.

Author avatar

Han Tan | Market Analyst

Published on June 30

Your Basket's Financial Footprint

Market-capitalisation breakdown for the basket, showing concentration among the largest holdings that anchor overall size and risk profile.

Key Takeaways for Investors:
  • Large-cap dominance tends to reduce volatility, offering more stable performance and closer tracking of broad-market moves.
  • Suitable as a core holding providing diversified exposure, not a high-risk speculative position.
  • Expect steady, long-term value appreciation rather than short-term explosive gains; growth is generally moderate.
Total Market Cap
  • MGA: $13.02B

  • UNP: $134.37B

  • XPO: $16.02B

  • Other

About This Group of Stocks

1

Our Expert Thinking

US tariff pressure on Japanese automotive and machinery exports is creating a strategic opportunity. As manufacturers relocate production to avoid these tariffs, companies providing industrial facilities, logistics networks, and manufacturing support in Mexico and Canada stand to gain significant business.

2

What You Need to Know

This collection focuses on North American companies across industrial real estate, rail transportation, airports, auto parts, and raw materials. These firms are uniquely positioned to benefit from Japanese companies establishing new manufacturing bases to maintain access to US markets.

3

Why These Stocks

These companies were selected because they offer direct exposure to the supply chain shift. They include strategically located transportation networks, industrial suppliers, and logistics providers with established operations in the regions most likely to attract relocated Japanese manufacturing.

Why You'll Want to Watch These Stocks

🌎

Global Shift in Action

These companies are at the frontlines of a major global manufacturing realignment. As Japanese firms respond to tariff pressure, billions in investment could flow to these North American beneficiaries.

🏭

The Mexico Manufacturing Boom

Mexico is becoming the new manufacturing hub for Japanese auto and machinery companies seeking tariff-free access to US markets. Companies with established operations there are perfectly positioned to capitalize.

🔄

Supply Chain Winners

As Japanese manufacturers relocate, they'll need everything from warehouses to rail transport to raw materials. This carefully selected group represents the companies most likely to win this new business.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Tech Stocks (AI Valuation Reset) Present Potential Entry

Tech Stocks (AI Valuation Reset) Present Potential Entry

Recent market turmoil, driven by concerns over AI stock valuations, has led to a significant drop in global markets. This correction creates a potential opportunity to invest in fundamentally sound technology companies at more attractive prices.

Walmart Succession Plan Explained | Market Effects

Walmart Succession Plan Explained | Market Effects

Walmart announced a CEO transition, with veteran John Furner taking the helm, which could create opportunities for competitors. This leadership change at a retail giant may cause short-term uncertainty, potentially benefiting other major players in the retail space.

Biotech Buyout Candidates (Post-Merck Acquisition)

Biotech Buyout Candidates (Post-Merck Acquisition)

Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.

Frequently Asked Questions